$16.13▴ 6.19%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$0.56cash per $1 profit
Weak
Much of its reported profit is not backed by operating cash.
Valuation
38th pctvs its own history
Fair
Its valuation is around the middle of its own recent range.
Revenue growth
+24.4%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Aurinia Pharmaceuticals Inc - Common Shares turns 56¢ of every reported profit-dollar into real cash. Much of its reported profit is not backed by operating cash. Revenue is growing strongly year over year. Its valuation is around the middle of its own recent range.
Key numbers
Valuation
EPS (TTM)$2.17
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin100.0%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$298.30M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.